Introduction
============

The optimal duration of anticoagulation in patients with unprovoked venous thromboembolism (VTE) is controversial. In these patients, the risk of recurrent events during the first year after anticoagulation is discontinued is between 5% and 10% [@b1]. The American College of Chest Physicians recommends a minimum of 3 months of anticoagulation therapy and to consider prolonged treatment in patients with low or moderate risk of major bleeding events [@b1]. To counsel patients, clinicians need accurate estimates of the risks of recurrent VTE and of major bleeding episodes with different therapeutic strategies to ensure that the benefits outweigh the risks of long-term secondary prevention. The risk of major bleeding after completing anticoagulant therapy is unknown in this patient population. Therefore, the incremental risks of major bleeding with various treatment strategies over and above the risk with no anticoagulant therapy are unclear. This systematic review and meta-analysis evaluates the rate of major bleeding episodes in high-risk patients participating in trials for the secondary prevention of recurrent VTE who received placebo or observation only (i.e. no anticoagulant therapy).

Patients and methods
====================

We searched MEDLINE (January 1, 1950 to August 31, 2013), EMBASE (January 1, 1980 to August 31, 2013), and the Cochrane Register of Controlled Trials using the OVID interface. Publications were also sought through a hand-search of potentially relevant journals. There were no restrictions on language, publication year, or type of publication. The search strategy included the MeSH terms *venous thrombosis, pulmonary embolism, aspirin, warfarin,* and *acenocoumarol*. The following terms were also added to the search strategy: *recurrent venous thromboembolism, oral anticoagulants, dabigatran, rivaroxaban, apixaban,* and *ximelagatran*. The outcomes were major bleeding and fatal bleeding as defined by ISTH [@b2] or per individual study. The methodological quality was evaluated using the Risk of Bias Assessment Tool from the Cochrane Handbook for randomized trials [@b3]. The primary measurement was bleeding event rates reported per 100 patient-years stratified according to the underlying treatment strategy with its associated 95% CIs. Pooled measurements were calculated using a random-effects model within the Stats Direct software (version 2.7.9; StatsDirect Ltd, Cheshire, UK). Heterogeneity was assessed using the *I*^2^ test [@b4].

Results and discussion
======================

Our systematic search identified 636 citations. A total of 11 trials assessing anticoagulation for secondary prevention after VTE were included in the analysis [@b5]--[@b15]. Eight studies were randomized placebo-controlled trials [@b5]--[@b9],[@b11],[@b12],[@b14], two studies compared vitamin K antagonist (VKA) treatment with observation [@b13],[@b15], and one study compared different durations of VKA therapy (the period of observation for major bleeding and fatal bleeding events after completing a fixed duration of anticoagulation was included in this analysis) [@b9],[@b10]. All studies were judged to be at low risk of bias according to the risk of bias assessment tool.

A total of 3965 patients were included in our analysis; 3630 were treated with placebo and 335 patients were simply observed for bleeding events (Table [1](#tbl1){ref-type="table"}). The total population was followed for a median of 23.9 months (range 6--40.3 months); the median follow-up for those receiving placebo was 14.3 months (6--25.2 months) and 37.2 months for those enrolled in observation without anticoagulation only arms (32.7--40.3 months). The majority of patients were male (median 57%, range 51%--63%); the mean age varied between 53 and 68 years; and most patients had unprovoked VTE (median 100%, range 57%--100%).

###### 

Characteristics of included studies

  Study                Patients   Treatment regimen (No. of patients) (group 1 vs. group 2 vs. group 3)                                  Study design               Follow-up duration (mean)                       Mean age (years)                     Men (%)                              Unprovoked VTE (%)   Antiplatelet use (%)   Active malignancy (%)   Normal renal function[\*](#tf1-2){ref-type="table-fn"} (%)   Major bleeding events (No.)   Fatal bleeding events (No.)                                                                                                                                                       
  -------------------- ---------- ------------------------------------------------------------------------------------------------------ -------------------------- ----------------------------------------------- ------------------------------------ ------------------------------------ -------------------- ---------------------- ----------------------- ------------------------------------------------------------ ----------------------------- ----------------------------- ---- ---- ------ ------ ------ ------ ------- ------------------------------------- ------------------------------------- ---- --- ---- --- --- --- ---
  DURAC 2 [@b10]       All VTE    Fixed duration VKA[†](#tf1-3){ref-type="table-fn"} (*n* = 111) vs. extended duration VKA (*n* = 116)   Open label, randomized     Fixed duration group followed for 40.3 months   65                                   64                                   --                   63                     59                      ─                                                            NR                            NR                            ─    NR   NR     ─      0      0      ─       NR                                    NR                                    ─    2   10   ─   1   2   ─
  LAFIT [@b12]         All VTE    Placebo (*n* = 83) vs. VKA (*n* = 79)                                                                  Double blind, randomized   10 months                                       58                                   59                                   ─                    53                     68                      ─                                                            100                           100                           ─    NR   NR     ─      NR     NR     ─       NR                                    NR                                    ─    0   3    ─   0   0   ─
  WODIT DVT [@b13]     DVT only   Observation (*n* = 133) vs. VKA (*n* = 134)                                                            Open label, randomized     37.2 months                                     68                                   67                                   ─                    61                     55                      ─                                                            100                           100                           ─    NR   NR     ─      0      0      ─       NR                                    NR                                    ─    2   4    ─   2   0   ─
  WODIT PE [@b15]      PE only    Observation (*n* = 91) vs. VKA (*n* = 90)                                                              Open label, randomized     32.7 months                                     61                                   63                                   ─                    NR                     NR                      ─                                                            57                            55                            ─    NR   NR     ─      0      0      ─       NR                                    NR                                    ─    1   2    ─   0   0   ─
  PREVENT [@b14]       All VTE    Placebo (*n* = 253) vs. Low intensity VKA (*n* = 255)                                                  Double blind, randomized   2.1 years                                       53[‡](#tf1-4){ref-type="table-fn"}   53[‡](#tf1-4){ref-type="table-fn"}   ─                    53                     53                      ─                                                            100                           100                           ─    NR   NR     ─      NR     NR     ─       NR                                    NR                                    ─    2   5    ─   1   0   ─
  THRIVE III [@b11]    All VTE    Placebo (*n* = 611) vs. ximelagatran 24 mg BID (*n* = 612)                                             Double blind, randomized   505 days                                        58                                   56                                   ─                    51                     54                      ─                                                            NR                            NR                            ─    NR   NR     ─      5      6      ─       110[§](#tf1-5){ref-type="table-fn"}   114[§](#tf1-5){ref-type="table-fn"}   ─    5   6    ─   0   0   ─
  RESONATE [@b9]       All VTE    Placebo (*n* = 659) vs. dabigatran 150 mg BID (*n* = 684)                                              Double blind, randomized   6 months                                        56                                   56                                   ─                    55                     56                      ─                                                            100                           100                           ─    NR   NR     ─      \< 1   \< 1   ─       70                                    70                                    ─    0   2    ─   0   0   ─
  EINSTEIN-EXT [@b5]   All VTE    Placebo (*n* = 590) vs. rivaroxaban 20 mg daily (*n* = 598)                                            Double blind, randomized   265 days                                        58                                   58                                   ─                    57                     59                      ─                                                            74                            73                            ─    NR   NR     ─      4.4    4.7    ─       63                                    62                                    ─    0   4    ─   0   0   ─
  AMPLIFY-EXT [@b8]    All VTE    Placebo (*n* = 826) vs. apixaban 5 mg BID (*n* = 811) vs. apixaban 2.5 mg BID (*n* = 840)              Double blind, randomized   12 months                                       57                                   56                                   57                   57                     58                      58                                                           91                            91                            93   13   11.8   14.3   2.2    1.1    1.8     68                                    71                                    71   4   1    2   0   0   0
  WARFASA [@b6]        All VTE    Placebo (*n* = 197) vs. ASA 100 mg daily (*n* = 205)                                                   Double blind, randomized   23.9 months                                     62                                   62                                   ─                    62                     66                      ─                                                            100                           100                           ─    0    100    ─      0      0      ─       NR                                    NR                                    ─    1   1    ─   0   0   ─
  ASPIRE [@b7]         All VTE    Placebo (*n* = 411) vs. ASA 100 mg daily (*n* = 411)                                                   Double blind, randomized   37.2 months                                     54                                   55                                   ─                    54                     55                      ─                                                            100                           100                           ─    0    100    ─      1      1      **─**   NR                                    NR                                    ─    6   8    ─   2   0   ─

ASA, acetyl salicylic acid; DVT, deep vein thrombosis; NR, not reported; PE, pulmonary embolism; VKA, vitamin K antagonist; VTE, venous thromboembolism.

Normal renal function is defined as creatinine clearance ≥ 80 mL min −1 (Cockcroft-Gault).

Standard-dose adjusted VKA unless otherwise indicated.

Median age.

Median creatinine clearance (Cockcroft-Gault).

The overall pooled major bleeding rate in patients who have completed anticoagulation for the secondary prevention of recurrent VTE (i.e. no longer on anticoagulant therapy) was 0.45 per 100 patient-years (95% CI 0.29--0.64, *I*^2^ = 0%). The pooled major bleeding rate for patients randomized to placebo was 0.42 per 100 patient-years (95% CI 0.25--0.62, *I*^2^ = 0%), and that for patients randomized to observation was 0.62 per 100 patient-years (95% CI 0.23--1.2, *I*^2^ = 0%) (Fig.[1](#fig01){ref-type="fig"}). Fatal bleeding events were rare with an overall pooled fatal bleeding rate of 0.14 per 100 patient-years (95% CI 0.057--0.26, *I*^2^ = 0%). In the studies reporting sites of major bleeding and fatal bleeding, intracranial hemorrhage (including subdural and subarachnoid bleeding) and gastrointestinal bleeding were most common.

![Forest plot of pooled proportions of major bleeding rates in patients randomized to placebo, observation, and overall (per 100 patient-years).](jth0012-0344-th12501-f1){#fig01}

Our systematic review demonstrates that patients not receiving anticoagulant or antiplatelet therapy for the secondary prevention of recurrent VTE also experience major bleeding events. This event rate needs to be accounted for and included in the risk-benefit ratio, along with the previously reported risk of recurrent VTE, on and off anticoagulation, and risk of major bleeding on anticoagulant therapy, when clinicians are deciding on the length of anticoagulation therapy for patients with unprovoked VTE [@b16]--[@b20].

The rate of major bleeding events for patients with VTE on oral anticoagulation has previously been reported to be approximately 2.1 per 100 patient-years (95% CI 1.6--2.6) [@b17]. Our review reported a risk of major bleeding of 0.45 per 100 patient-years (95% CI 0.29--0.64) for similar patients not receiving anticoagulant therapy. Therefore, the incremental risk of major bleeding associated with anticoagulant therapy is approximately 1.5 per 100 patient-years. A recent systematic review and network meta-analysis reported that the use of VKA was associated with the greatest risk of major bleeding events in comparison to placebo or observation (OR 5.24, 95% credible interval \[CrI\] 1.78--18.25) [@b20]. In that review, the new oral anticoagulant apixaban, at two different treatment doses, was associated with the lowest risk of major bleeding events relative to placebo or observation.

It is interesting to note that the rates of major bleeding are higher in patients randomized to observation than those on placebo, although this finding is not significant. This may be attributed to different definitions of major bleeding used among the trials. All three trials randomizing patients to observation were published between 1997 and 2003―that is, before the ISTH criteria were established.

Our review has several strengths and limitations. First, all bleeding events were independently adjudicated; second, there was no heterogeneity identified between studies. Limitations of this study include the relatively small sample size of patients randomized to observation and generalizability to clinical practice. With respect to this latter concern, the patient population was extracted from RCTs. These patients are selected for participation, are likely younger, and generally do not have a history of bleeding events and severe comorbidities as they are often excluded from such studies, which may underestimate the true "real-world" bleeding risk and make our reported rate a conservative estimate. Timing of major bleeding events and known risk factors for major bleeding (antiplatelet use, moderate renal dysfunction, active malignancy, etc.) were not consistently reported in all trials, and therefore subgroup analyses could not be conducted. Last, observational prospective cohort studies were not included in the review. Although this could provide more insight into "real-world" bleeding risks, it may have significantly increased heterogeneity given the potential lack of independent adjudication or the use of standardized definitions of major bleeding.

In conclusion, our review suggests that the incidence of major bleeding events is non-negligible in patients receiving no treatment and may change the estimate of the incremental harm-benefit ratio clinicians consider when discussing anticoagulation for secondary prevention of recurrent VTE with patients.
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